Five things for pharma marketers to know: Tuesday, February 9, 2016

1. The FDA's arthritis advisory committee is scheduled to meet today to discuss Celltrion's application for a biosimilar version of Remicade, Johnson and Johnson's best-selling drug used to treat a number of indications including Crohn's disease and rheumatoid arthritis. (FDA)

2. Sen. Ron Wyden (D-Ore.) is questioning how the panelists involved in changing painkiller prescribing were selected and screened. About a third of the panelists on the Interagency Pain Research Coordinating Committee have financial ties to painkiller manufacturers. (AP)

3. Novartis signed contracts with insurers Cigna and Aetna that tie the price of its new heart-failure drug, Entresto, to how well it performs in patients. As part of the deal, the drug's base price and rebate will fluctuate based on the number of hospitalizations and savings to the health plan. (Reuters)

4. Sanofi said it doesn't expect much profit growth this year, in part due to declining sales of its insulin, Lantus. Sales of Lantus fell 13% to roughly $1.74 billion in the fourth quarter of 2015. (Bloomberg)

5. The UK's National Institute for Health and Care Excellence said it will cover Amgen's PCSK9 inhibitor, Repatha, but not Sanofi's and Regeneron's drug, Praluent. The cost watchdog said Praluent's benefits are uncertain. (Reuters)